Variety of qualified sufferers: CDEC talked about the uncertainty in the quantity of sufferers with moderately extreme to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be labeled as acquiring delicate or moderate disease may have a serious b